Chinese Clinical Pre-TCE Single Overseas Authorization Sets New Record! Hengtai Technology (07666) and Deerfield Achieve First Strategic Alliance Milestone

On June 30th, Insilico Medicine, a global leader in AI-driven drug delivery innovations, announced a strategic alliance with Deerfield Management, a top global health investment and innovation platform, to accelerate the global development of the next-generation immunotherapy. Insilico Medicine, with the support of Deerfield, has officially signed a global exclusive licensing agreement with Boulevard Bio, a US biotechnology company established by Deerfield, granting it the rights to develop, manufacture, and commercialize its self-developed trispecific TCE (T Cell Engager) MTS-128 project worldwide. Insilico Medicine will receive an upfront payment of $20 million and is eligible for milestone payments of up to $1.6 billion for development, registration, and commercialization, in addition to tiered royalties based on product sales. The total potential value of this overseas licensing transaction for Insilico Medicine exceeds $1.6 billion, setting a new record for the overseas licensing transaction amount of a Chinese pharmaceutical company's preclinical TCE project. This is also an important milestone for the internationalization of Chinese AI-driven drug delivery innovation. Insilico Medicine's self-developed NanoForge has achieved a deep integration of AI protein design, delivery system development, and innovative therapy development, receiving dual validation from top global capital and industry partners, marking the transition of AI-driven drug delivery platforms from early technology validation to global commercial value realization. Dr. Rui Caidada, Chairman and CEO of Insilico Medicine, stated, "This transaction is not only a milestone for the strategic alliance between Insilico Medicine and Deerfield, but also a key moment for Chinese AI-driven drug delivery innovation. The MTS-128 project demonstrates the ability of NanoForge to drive next-generation innovative drug development. This is just the beginning, and we believe NanoForge will continue to produce globally competitive innovative assets. With the deep integration of AI and drug delivery technology, we look forward to promoting the development of original therapies in China from concept validation to global development and bringing truly accessible innovative treatment options to patients." Deerfield is one of the most active and influential professional investment institutions in the global life sciences and healthcare field, not only involved in capital investment but also proficient in deep involvement in enterprise strategy, clinical development, global registration, industry cooperation, and international business expansion. It is a top healthcare investment platform with the combined capabilities of "industry resources + clinical translation + global capital." Deerfield has invested in over 200 healthcare enterprises, managing over $16 billion in assets, and has long-term investments and support for multiple international leading biotechnology companies and innovation platforms, deeply deploying in the fields of oncology, autoimmune diseases, RNA therapy, gene editing, AI pharmaceuticals, and other cutting-edge biotechnology and innovative drug areas worldwide.